Sage Therapeutics, Inc. — Operating Income by Fiscal Year
13 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/208b7726-a638-4dac-82db-aab000c8c57b/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2024 | $-432.4M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-017909 |
| FY 2023 | $-579.8M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-014934 |
| FY 2022 | $-547.0M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-002964 |
| FY 2021 | $-460.9M | 2021-01-01 – 2021-12-31 | evidence 0001564590-22-006495 |
| FY 2020 | $596.2M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-007819 |
| FY 2019 | $-708.1M | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-007021 |
| FY 2018 | $-393.2M | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-003191 |
| FY 2017 | $-273.2M | 2017-01-01 – 2017-12-31 | evidence 0001564590-18-002772 |
| FY 2016 | $-160.2M | 2016-01-01 – 2016-12-31 | evidence 0001564590-17-002434 |
| FY 2015 | $-94.7M | 2015-01-01 – 2015-12-31 | evidence 0001193125-16-485683 |
| FY 2014 | $-33.8M | 2014-01-01 – 2014-12-31 | evidence 0001193125-15-081090 |
| FY 2013 | $-18.3M | 2013-01-01 – 2013-12-31 | evidence 0001193125-15-081090 |
| FY 2012 | $-9.6M | 2012-01-01 – 2012-12-31 | evidence 0001193125-15-081090 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).